SSC clinical trials at UCSD
1 research study open to eligible people
Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
open to eligible people ages 18 years and up
This is an open-label, "non comparative", non-randomized, Phase II study. Patients will be enrolled in 2 treatment arms
La Jolla, California and other locations